Effectiveness and Cost-Effectiveness of 360 Disease-Modifying Treatment Escalation Sequences in Multiple Sclerosis

Research output: Contribution to journalArticleAcademicpeer-review

12 Downloads (Pure)

Abstract

Objectives: The rapid expansion in treatment options for relapsing-remitting multiple sclerosis (RRMS) of the past decade requires clinical decision making on the sequential prescription of these treatments. Here, we compare 360 treatment escalation sequences for patients with RRMS in terms of health outcomes and societal costs in The Netherlands. Methods: We use a microsimulation model with a societal perspective, developed in collaboration with MS neurologists, to estimate the effectiveness and cost-effectiveness of 360 treatment sequences starting with first-line therapies in RRMS. This model integrated data on disease progression, disease-modifying treatment efficacy, clinical decision rules, age-dependent relapse rates, quality of life, healthcare, and societal costs. Results: Costs and health outcomes were overlapping among different treatment escalation sequences. In our model for RRMS treatment, optimal lifetime health outcomes (20.24 ± 1.43 quality-adjusted life-years [QALYs], 6.11 ± 0.30 relapses) were achieved with the sequence peginterferon-dimethyl fumarate-ocrelizumab-natalizumab-alemtuzumab. The most cost-effective sequence (peginterferon-glatiramer acetate-ocrelizumab-cladribine-alemtuzumab) yielded numerically worse health outcomes per patient (19.59 ± 1.43 QALYs, 6.64 ± 0.43 relapses), but resulted in €98 127 ± €19 134 less costs than the most effective treatment sequence. Conclusions: Effectiveness estimates of treatments have overlapping confidence intervals but the treatment sequence that yields most QALYs is not the most cost-effective option, also when taking uncertainty into account. It is important that neurologists are aware of cost constraints and its relationship with prescription behavior, but treatment decisions should be individually tailored.

Original languageEnglish
Pages (from-to)984-991
Number of pages8
JournalValue in Health
Volume25
Issue number6
Early online date15 Dec 2021
DOIs
Publication statusE-pub ahead of print - 15 Dec 2021

Bibliographical note

Funding Information:
Funding/Support: Financial support for this study was provided by an unrestricted grant from the Erasmus University Medical Center. The funding agreement ensured the authors’ independence in designing the study, interpreting the data, and writing and publishing the report.

Publisher Copyright:
© 2021 ISPOR - The professional society for health economics and outcomes research

Fingerprint

Dive into the research topics of 'Effectiveness and Cost-Effectiveness of 360 Disease-Modifying Treatment Escalation Sequences in Multiple Sclerosis'. Together they form a unique fingerprint.

Cite this